The United States Patent and Trademark Office, or USPTO issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
